Treace Medical Concepts, Inc. Revenue
Treace Medical Concepts, Inc. (TMCI) reported Revenue of $45.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-08-07
- Treace Medical Concepts, Inc. revenues for the quarter ending 2026-06-30 was $45.38M, a 4.24% decline year-over-year.
- Treace Medical Concepts, Inc. revenues for the quarter ending 2026-03-31 was $47.20M, a 10.22% decline year-over-year.
- Treace Medical Concepts, Inc. revenues for the quarter ending 2025-12-31 was $62.52M, a 9.01% decline year-over-year.
- Treace Medical Concepts, Inc. revenues for the quarter ending 2025-09-30 was $50.21M, a 11.37% increase year-over-year.
- Treace Medical Concepts, Inc. revenues for fiscal 2025 was $212.69M, a 1.59% increase from fiscal 2024.
- Treace Medical Concepts, Inc. revenues for fiscal 2024 was $209.36M, a 11.89% increase from fiscal 2023.
- Treace Medical Concepts, Inc. revenues for fiscal 2023 was $187.12M, a 31.92% increase from fiscal 2022.
- Treace Medical Concepts, Inc. revenues for fiscal 2022 was $141.84M, a 50.22% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.38M 10-Q · filed 2026-08-07 | $92.57M 10-Q · filed 2026-08-07 | $155.09M derived: sum of 3 quarters · filed 2026-08-07 | $205.31M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $47.20M 10-Q · filed 2026-05-08 | $109.72M derived: sum of 2 quarters · filed 2026-05-08 | $159.93M derived: sum of 3 quarters · filed 2026-05-08 | $207.32M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $62.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $112.73M derived: sum of 2 quarters · filed 2026-02-27 | $160.12M derived: sum of 3 quarters · filed 2026-08-07 | $212.69M 10-K · filed 2026-02-27 |
| 2025-09-30 | $50.21M 10-Q · filed 2025-11-06 | $97.60M derived: sum of 2 quarters · filed 2026-08-07 | $150.17M 10-Q · filed 2025-11-06 | $218.88M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $47.39M 10-Q · filed 2026-08-07 | $99.96M 10-Q · filed 2026-08-07 | $168.66M derived: sum of 3 quarters · filed 2026-08-07 | $213.75M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $52.57M 10-Q · filed 2026-05-08 | $121.28M derived: sum of 2 quarters · filed 2026-05-08 | $166.36M derived: sum of 3 quarters · filed 2026-05-08 | $210.82M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $68.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $113.79M derived: sum of 2 quarters · filed 2026-02-27 | $158.25M derived: sum of 3 quarters · filed 2026-02-27 | $209.36M 10-K · filed 2026-02-27 |
| 2024-09-30 | $45.09M 10-Q · filed 2025-11-06 | $89.54M derived: sum of 2 quarters · filed 2025-11-06 | $140.65M 10-Q · filed 2025-11-06 | $202.86M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $44.45M 10-Q · filed 2025-08-07 | $95.56M 10-Q · filed 2025-08-07 | $157.78M derived: sum of 3 quarters · filed 2026-02-27 | $198.53M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $51.11M 10-Q · filed 2025-05-08 | $113.32M derived: sum of 2 quarters · filed 2026-02-27 | $154.08M derived: sum of 3 quarters · filed 2026-02-27 | $196.03M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $62.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $102.97M derived: sum of 2 quarters · filed 2026-02-27 | $144.92M derived: sum of 3 quarters · filed 2026-02-27 | $187.12M 10-K · filed 2026-02-27 |
| 2023-09-30 | $40.76M 10-Q · filed 2024-11-05 | $82.71M derived: sum of 2 quarters · filed 2024-11-05 | $124.91M 10-Q · filed 2024-11-05 | $174.68M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $41.95M 10-Q · filed 2024-08-06 | $84.15M 10-Q · filed 2024-08-06 | $133.92M derived: sum of 3 quarters · filed 2025-02-27 | $166.97M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $42.20M 10-Q · filed 2024-05-07 | $91.96M derived: sum of 2 quarters · filed 2025-02-27 | $125.02M derived: sum of 3 quarters · filed 2025-02-27 | $154.99M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $49.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $82.82M derived: sum of 2 quarters · filed 2025-02-27 | $112.79M derived: sum of 3 quarters · filed 2025-02-27 | $141.84M 10-K · filed 2025-02-27 |
| 2022-09-30 | $33.05M 10-Q · filed 2023-11-09 | $63.02M derived: sum of 2 quarters · filed 2023-11-09 | $92.07M 10-Q · filed 2023-11-09 | $125.51M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $29.97M 10-Q · filed 2023-08-09 | $59.01M 10-Q · filed 2023-08-09 | $92.45M derived: sum of 3 quarters · filed 2024-02-27 | $114.07M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $29.05M 10-Q · filed 2023-05-09 | $62.49M derived: sum of 2 quarters · filed 2024-02-27 | $84.11M derived: sum of 3 quarters · filed 2024-02-27 | $104.76M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $33.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $55.06M derived: sum of 2 quarters · filed 2024-02-27 | $75.71M derived: sum of 3 quarters · filed 2024-02-27 | $94.42M 10-K · filed 2024-02-27 |
| 2021-09-30 | $21.62M 10-Q · filed 2022-11-09 | $42.27M derived: sum of 2 quarters · filed 2022-11-09 | $60.98M 10-Q · filed 2022-11-09 | $85.08M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-06-30 | $20.65M 10-Q · filed 2022-08-10 | $39.36M 10-Q · filed 2022-08-10 | $63.47M derived: sum of 3 quarters · filed 2023-03-08 | $77.73M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-03-31 | $18.71M 10-Q · filed 2022-05-06 | $42.81M derived: sum of 2 quarters · filed 2023-03-08 | $57.08M derived: sum of 3 quarters · filed 2023-03-08 | $64.82M derived: sum of 4 quarters · filed 2023-03-08 |
| 2020-12-31 | $24.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $38.37M derived: sum of 2 quarters · filed 2023-03-08 | $46.11M derived: sum of 3 quarters · filed 2023-03-08 | $57.37M 10-K · filed 2023-03-08 |
| 2020-09-30 | $14.27M 10-Q · filed 2021-11-04 | $22.00M derived: sum of 2 quarters · filed 2021-11-04 | $33.26M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $7.74M 10-Q · filed 2021-08-05 | $19.00M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $11.26M 10-Q · filed 2021-05-25 | |||
| 2019-12-31 | $39.42M 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |